CHED 1273 |
| The research utilizes the apoptotic pathway to combat hepatocellular carcinoma (HCC). Benzamide riboside (BR) accomplishes this by inhibiting guanylate biosynthesis. Caspase 3 and 9 levels increase and caspase 8 decreases. In vitro testing consists of BR delivered directly to N1S1 cancer cells. In vivo testing is conducted via intrarterial N1S1 delivery. We hypothesize that BR can reduce or eliminate HCC cells. We believe that intrarterial BR delivery can improve the effectiveness of drug delivery. Cancer cells are cultured and treated with varying BR amounts. The rats are inoculated with N1S1 cells into the left hepatic median lobe. BR reaches the tumor via direct delivery into the arterial branch leading to tumor. The livers are imaged using fluoroscopy, MRI, ultrasound modalities. Intrarterial delivery of BR decreases tumor growth rate versus systemic intravenous delivery. Increased BR Concentration results in an increase in Caspase 3 and 9, and a decrease in Caspase 8. |
|
Undergraduate Research Poster Session: Medicinal Chemistry
2:00 PM-4:00 PM, Monday, April 7, 2008 Morial Convention Center -- Hall A, Poster
Division of Chemical Education |